Diabetic cardiomyopathy (DCM) is a leading cause of mortality in patients with diabetes. DCM is a leading cause of mortality in patients with diabetes. We used both in vitro and in vivo experiments to investigate the hypothesis that sophocarpine (SPC), a natural quinolizidine alkaloid derived from a Chinese herb, could protect against DCM. We used hyperglycemic myocardial cells and a streptozotocin (STZ)-induced type 1 diabetes mellitus mouse model. SPC protected myocardial cells from hyperglycemia-induced injury by improving mitochondrial function, suppressing inflammation, and inhibiting cardiac apoptosis. The SPC treatment significantly inhibited the activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling in high-glucosestimulated inflammatory responses. Moreover, SPC significantly slowed the development and progression of DCM in STZ-induced diabetic mice. These results show that SPC suppresses NF-κB-mediated inflammation both in vitro and in vivo and may be used to treat DCM.
CITATION STYLE
Zou, F., Wang, L., Liu, H., Wang, W., Hu, L., Xiong, X., … Yang, R. (2019). Sophocarpine suppresses NF-κB mediated inflammation both in vitro and in vivo and inhibits diabetic cardiomyopathy. Frontiers in Pharmacology, 10(OCT). https://doi.org/10.3389/fphar.2019.01219
Mendeley helps you to discover research relevant for your work.